1
|
Francolini G, Cerbai C, Loi M, Di Cataldo V, Detti B, Simontacchi G, Ciccone L, Masi L, Doro R, Allegra A, Salvestrini V, Mattioli C, Frosini G, Burchini L, Aquilano M, Stocchi G, Desideri I, Livi L. PD-0411 Predictive factors of late GU toxicity after Cyberknife re-irradiation for locally recurrent PCa. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02846-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Loi M, Bonucci I, Masi L, Doro R, Francolini G, Di Cataldo V, Bonomo P, Visani L, Tempobono M, Bellosi N, Pazzaglini S, Cassinelli M, Simontacchi G, Greto D, Desideri I, Lucidi S, Aquilano M, Livi L. PO-1469 CT-Guided Fiducial Placement for Robotic Stereotactic Body Radiotherapy: Efficacy and Safety. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03433-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Aquilano M, Loi M, Livi L, Nuyttens J. PO-1261 Is SBRT an effective treatment in metastatic lung cancer with oligoprogressive disease? Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03225-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
4
|
Francolini G, Detti B, Di Cataldo V, Caini S, Alitto A, Parisi S, Demofonti C, Bruni A, Ingrosso G, Timon G, Tagliagambe A, Aquilano M, Ciccone L, Salvestrini V, Frosini G, Cerbai C, Allegra A, Burchini L, Desideri I, Mangoni M, Meattini I, Livi L. OC-0605 Early outcomes of a randomized trial of SBRT and Abiraterore in mCPRC: ARTO trial NCT03449719. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02627-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Francolini G, Di Cataldo V, Detti B, Allegra A, Burchini L, Ciccone L, Cerbai C, Mattioli C, Frosini G, Guerrieri B, Aquilano M, Salvestrini V, Chiti A, Sollini M, Simontacchi G, Desideri I, Livi L. PO-1363 Detection rate of 68Ga-PSMA PET/CT from a prospective study: PSICHE trial (NCT05022914). Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03327-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Francolini G, Loi M, Di Cataldo V, Detti B, Stocchi G, Masi L, Doro R, Scoccimarro E, Bellini C, Aquilano M, Allegra AG, Peruzzi A, Guerrieri B, Morelli I, Valzano M, Ciccone LP, Salvestrini V, Desideri I, Livi L. Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years. Clin Oncol (R Coll Radiol) 2021; 34:50-56. [PMID: 34810069 DOI: 10.1016/j.clon.2021.11.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 10/07/2021] [Accepted: 11/02/2021] [Indexed: 12/26/2022]
Abstract
AIMS In 2018, we published early results from a cohort of patients treated with stereotactic body radiotherapy (SBRT) after previous radiotherapy with definitive or postoperative intent. We sought to provide extended follow-up of this cohort to confirm the safety and efficacy of this approach in a real-world scenario. MATERIALS AND METHODS Fifty patients affected by local relapse after previous definitive or postoperative radiotherapy were treated with SBRT. Treatment provided a total dose of 30 Gy in five fractions. Data about biochemical relapse-free survival (BRFS) and metastasis-free survival (MFS), together with adverse events, were analysed. Toxicity was reported according to Common Terminology Criteria for Adverse Events (CTCAE) score v.4.03. RESULTS After a median follow-up of 48.2 months, the median BRFS was 43 months. A Gleason score >7 and concomitant androgen deprivation therapy were shown to be predictors of the worst BRFS (hazard ratio 2.42, 95% confidence interval 1.09-5.41, P = 0.02; hazard ratio 2.83, 95% confidence interval 1.17-6.8, P = 0.02, respectively). The median MFS was not reached; concomitant androgen deprivation therapy was confirmed to be predictive of the worst MFS (hazard ratio 4.75, 95% confidence interval 1.52-14.8, P = 0.007). Late grade 1 and 2 rectal and bladder toxicity occurred in three (6%) and 13 (26%) patients, respectively. One patient experienced both grade 3 acute and chronic bladder toxicity. CONCLUSION Salvage SBRT re-irradiation after previous postoperative or definitive radiotherapy for local prostate cancer recurrence confirmed promising results in terms of oncological outcomes and the safety of this approach.
Collapse
Affiliation(s)
- G Francolini
- Azienda Ospedaliera Universitaria Careggi, Radiotherapy Unit, Florence, Italy.
| | - M Loi
- Azienda Ospedaliera Universitaria Careggi, Radiotherapy Unit, Florence, Italy
| | - V Di Cataldo
- CyberKnife Center, L'Istituto Fiorentino di Cura e Assistenza, Florence, Italy
| | - B Detti
- Azienda Ospedaliera Universitaria Careggi, Radiotherapy Unit, Florence, Italy
| | - G Stocchi
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - L Masi
- Department of Medical Physics, Radiation Oncology L'Istituto Fiorentino di Cura e Assistenza, Florence, Italy
| | - R Doro
- Department of Medical Physics, Radiation Oncology L'Istituto Fiorentino di Cura e Assistenza, Florence, Italy
| | - E Scoccimarro
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - C Bellini
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - M Aquilano
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - A G Allegra
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - A Peruzzi
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - B Guerrieri
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - I Morelli
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - M Valzano
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - L P Ciccone
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - V Salvestrini
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - I Desideri
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| | - L Livi
- Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy
| |
Collapse
|
7
|
Desideri I, Francolini G, Ciccone LP, Stocchi G, Salvestrini V, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L. Correction to: Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy facility. Support Care Cancer 2021; 30:1891-1892. [PMID: 34750667 PMCID: PMC8575545 DOI: 10.1007/s00520-021-06665-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Isacco Desideri
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy.
| | - G Francolini
- Radiation Oncology Unit, University of Florence, Florence, Italy.,CyberKnife Center, Istituto Fiorentino di Cura ed Assistenza, Florence, Italy.,Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - L P Ciccone
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - G Stocchi
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - V Salvestrini
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - M Aquilano
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - D Greto
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - P Bonomo
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - I Meattini
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy.,Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - V Scotti
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - S Scoccianti
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - G Simontacchi
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - L Livi
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| |
Collapse
|
8
|
Francolini G, Di Cataldo V, Detti B, Loi M, Ghirardelli P, Vavassori V, Nicosia L, Alongi F, Triggiani L, La Mattina S, Allegra A, Cerbai C, Aquilano M, Burchini L, Mattioli C, Peruzzi A, Lucidi S, Scoccimarro E, Mariotti M, Salvestrini V, Stocchi G, Ciccone L, Desideri I, Livi L. Concomitant immuno-radiotherapy in metastatic renal cell carcinoma: multicenter analysis. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03166-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Francolini G, Bellini C, Di Cataldo V, Detti B, Bruni A, Alicino G, Triggiani L, La Mattina S, D'Angelillo RM, Demofonti C, Mazzola R, Cuccia F, Alongi F, Aquilano M, Allegra AG, Ciccone LP, Burchini L, Salvestrini V, Morelli I, Frosini G, Desideri I, Livi L. Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis. Clin Oncol (R Coll Radiol) 2021; 34:57-62. [PMID: 34598843 DOI: 10.1016/j.clon.2021.09.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 08/16/2021] [Accepted: 09/20/2021] [Indexed: 01/22/2023]
Abstract
AIMS Currently, when nodal pelvic oligorecurrent disease is detected, no standard treatment option is recommended. One possible salvage option is nodal stereotactic body radiotherapy (SBRT). Here we analysed recurrence patterns after nodal SBRT in patients affected by pelvic oligometastatic relapse after radical prostatectomy, and androgen deprivation therapy (ADT)-free survival in this population. MATERIALS AND METHODS Data on 93 patients consecutively treated in five different institutions for pelvic oligorecurrent disease were reviewed. Inclusion criteria were biochemical recurrence after radical prostatectomy and imaging showing three or fewer metachronous lymphoadenopathies under aortic bifurcation. Patients underwent SBRT on all sites of disease. Concomitant ADT was allowed. RESULTS After a median follow-up of 20 months (interquartile range 11-41), 57 patients had post-SBRT radiological evidence of relapse, for a median disease-free survival (DFS) of 15 months (95% confidence interval 9-24). Concomitant ADT was administered in 20 patients (21.5%). Overall, eight (8.6%), 21 (22.6%) and 28 (30.1%) patients had prostate bed only, pelvic nodal or distant relapse, respectively. The median ADT-free survival was not reached. Concomitant ADT, International Society for Urologic Pathology pattern at diagnosis < or ≥3, time to relapse ≤ or >12 months, prostate-specific antigen at recurrence < or ≥1.10 ng/ml and prostate-specific membrane antigen staging were not significantly associated with DFS. After relapse, 42 patients (45.2%) received a second SBRT course. CONCLUSION Nodal SBRT yielded encouraging DFS and ADT-free survival in this population. Only a minority of patients developed prostate bed recurrence, suggesting that local treatment may be safely avoided. A consistent percentage of patients could be managed with a second SBRT course.
Collapse
Affiliation(s)
- G Francolini
- Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
| | - C Bellini
- Department of Biomedical, Experimental and Clinical Sciences, "Mario Serio", University of Florence, Florence, Italy
| | | | - B Detti
- Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy.
| | - A Bruni
- Radiation Oncology Unit, Modena Hospital, Modena, Italy
| | - G Alicino
- Radiation Oncology Unit, Modena Hospital, Modena, Italy
| | - L Triggiani
- Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy
| | - S La Mattina
- Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy
| | - R M D'Angelillo
- Department of Radiation Oncology, Policlinico Tor Vergata University, Rome, Italy
| | - C Demofonti
- Department of Radiation Oncology, Policlinico Tor Vergata University, Rome, Italy
| | - R Mazzola
- Radiation Oncology Department, IRCCS, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy
| | - F Cuccia
- Radiation Oncology Department, IRCCS, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy
| | - F Alongi
- Radiation Oncology Department, IRCCS, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy
| | - M Aquilano
- Department of Biomedical, Experimental and Clinical Sciences, "Mario Serio", University of Florence, Florence, Italy
| | - A G Allegra
- Department of Biomedical, Experimental and Clinical Sciences, "Mario Serio", University of Florence, Florence, Italy
| | - L P Ciccone
- Department of Biomedical, Experimental and Clinical Sciences, "Mario Serio", University of Florence, Florence, Italy
| | - L Burchini
- Department of Biomedical, Experimental and Clinical Sciences, "Mario Serio", University of Florence, Florence, Italy
| | - V Salvestrini
- Department of Biomedical, Experimental and Clinical Sciences, "Mario Serio", University of Florence, Florence, Italy
| | - I Morelli
- Department of Biomedical, Experimental and Clinical Sciences, "Mario Serio", University of Florence, Florence, Italy
| | - G Frosini
- Department of Biomedical, Experimental and Clinical Sciences, "Mario Serio", University of Florence, Florence, Italy
| | - I Desideri
- Department of Biomedical, Experimental and Clinical Sciences, "Mario Serio", University of Florence, Florence, Italy
| | - L Livi
- Department of Biomedical, Experimental and Clinical Sciences, "Mario Serio", University of Florence, Florence, Italy
| |
Collapse
|
10
|
Francolini G, Loi M, Salvestrini V, Mangoni M, Detti B, Di Cataldo V, Aquilano M, Pinzani P, Salvianti F, Desideri I, Mariotti M, Garlatti P, Stocchi G, Ciccone LP, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L. Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275). Clin Exp Metastasis 2021; 38:451-458. [PMID: 34410545 PMCID: PMC8510932 DOI: 10.1007/s10585-021-10118-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Accepted: 08/10/2021] [Indexed: 11/12/2022]
Abstract
In our institution, a prospective observational trial testing micro-RNA (miRNA) and ARV7 mutational status in metastatic, castration resistant prostate cancer (mCRPC), is currently recruiting (PRIMERA trial, NCT04188275). A pre-planned interim analysis was performed when 50% of the planned accrual was reached. In this report, we explored the predictive value of Circulating Tumor Cell (CTC) detection in mCRPC patients undergoing 1st line therapy. Moreover, ARV7, ARFL, PSMA and PSA expression on CTC was reported to explore potential correlation with patient prognosis and response to therapy. PRIMERA is a prospective observational trial enrolling mCRPC patients undergoing standard treatment (ARTA + ADT) after I line ADT failure. Clinical and pathological features were collected. Outcomes selected for this preliminary analysis were time to castration resistance (TTCR), PSA at 8 weeks after ARTA therapy start, PSA drop at 8 weeks, Overall PSA drop, PSA nadir. Correlation between these outcomes and CTC detection was tested. Expression of ARV7, ARFL, PSA and PSMA was explored in CTC+ patients to assess their prevalence in this cohort and their impact on selected outcomes. Median TTCR was significantly shorter in CTC+ vs CTC− patients (32.3 vs 75 months, respectively, p = 0.03) and in ARFL+ vs ARFL− patients (30.2 vs 51.1 months, respectively, p = 0.02). ARV7, PSMA and PSA expression on CTC had no impact on median TTCR, nor on biochemical response to therapy. Patients in whom CTC and ARFL expression were detected had significant reduced TTCR. However, PSA response was not influenced by CTCs detection and specific biomarkers expression.
Collapse
Affiliation(s)
- G Francolini
- Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Largo G. A. Brambilla 3, 50134, Florence, Italy
| | - M Loi
- Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Largo G. A. Brambilla 3, 50134, Florence, Italy
| | - V Salvestrini
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - M Mangoni
- Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Largo G. A. Brambilla 3, 50134, Florence, Italy
| | - B Detti
- Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Largo G. A. Brambilla 3, 50134, Florence, Italy.
| | - V Di Cataldo
- Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Largo G. A. Brambilla 3, 50134, Florence, Italy
| | - M Aquilano
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - P Pinzani
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - F Salvianti
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - I Desideri
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - M Mariotti
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - P Garlatti
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - G Stocchi
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - L P Ciccone
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - S Lucidi
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - G Salvatore
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - M Sottili
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy
| | - I Meattini
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy.,Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Largo G. A. Brambilla 3, 50134, Florence, Italy
| | - L Livi
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy.,Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Largo G. A. Brambilla 3, 50134, Florence, Italy
| |
Collapse
|
11
|
Visani L, Ratosa I, Scoccimarro E, Becherini C, Saieva C, Desideri I, Scotti V, Ozarem M, Ribnikar D, Aquilano M, Cerbai C, Orzalesi L, Bernini M, Sanchez L, Nori J, Bianchi S, Meattini I, Livi L. OC-0071 Safety and efficacy of concomitant radiation and CDK4/6 inhibitors in breast cancer patients. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06765-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
12
|
Francolini G, Loi M, Di Cataldo V, Detti B, Stocchi G, Allegra A, Bellini C, Aquilano M, Ciccone L, Mariotti M, Salvestrini V, Scoccimarro E, Valzano M, Simontacchi G, Bonomo P, Lucidi S, Desideri I, Meattini I, Livi L. PO-1316 Stereotactic radiotherapy in recurrent prostate cancer after postoperative or definitive irradiation. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07767-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
13
|
Ciccone L, Zani M, Scoccimarro E, Aquilano M, Banini M, Caprara L, Mariotti M, Salvestrini V, Becherini C, Desideri I, Marrazzo L, Pallotta S, Livi L, Bonomo P. PO-0997 Lack of CTV_P2 is not associated with a detrimental outcome in oropharyngeal cancer: a cohort study. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07448-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Francolini G, Bellini C, Di Cataldo V, Detti B, Bruni A, Alicino G, Triggiani L, La Mattina S, D’Angelillo R, Demofonti C, Mazzola R, Cuccia F, Alongi F, Aquilano M, Allegra A, Ciccone L, Stocchi G, Salvestrini V, Guerrieri B, Livi L. PO-1366 Pattern of recurrence after SBRT in prostate cancer patients with nodal pelvic relapse. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07817-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Desideri I, Francolini G, Ciccone LP, Stocchi G, Salvestrini V, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L. Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy facility. Support Care Cancer 2021; 29:2931-2937. [PMID: 33006676 PMCID: PMC7531068 DOI: 10.1007/s00520-020-05793-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 09/18/2020] [Indexed: 01/09/2023]
Abstract
PURPOSE In the last months, Italy faced a COVID-19 emergency and implemented preventive measures in order to protect patients and healthcare providers from a disease outbreak. The pandemic control strategies impacted patient experience directly. Questionnaires evaluating patients reported measures (PREMs) may assess critical issues and represent a helpful tool to measure the patient perception of healthcare service. Our aim was to prospectively assess patient satisfaction about doctor-patient interaction in a high-volume radiation therapy and oncology center during the COVID-19 pandemic. METHODS Cancer patients receiving either systemic and/or radiation treatment underwent a survey. Two validated questionnaires (EORTC QLQ-C30, FACIT-TS-G version 1) and 14 specific questions evaluating patients' perception of COVID-19 measures were administered. RESULTS One hundred twenty-five patients admitted to our department from 1-30 April 2020 completed the questionnaires. The majority (66.4%) of patients were women and the most common disease was breast cancer (40%). The average Global Health Status (GHS) of EORTC QLQ-C30 was 61.67. Emotional functioning, social, and cognitive domains obtained scores of 75.48, 80.13, and 84.67, respectively. FACIT-TS-G results revealed 120 patients rated the treatments effective and 108 patients thought the side effects were the same as expected or better. Most (89.6%) rated their treatment good, very good, or excellent. Concerning COVID-19-related questions, patients reported overall very good level of information. CONCLUSIONS Despite the introduction of strict COVID-19 control measures, there was a high level of cancer outpatient satisfaction. The satisfaction levels may influence compliance, continuity of treatments, and patient-doctor communication, impacting the quality of clinical care in the next phases of the pandemic.
Collapse
Affiliation(s)
- Isacco Desideri
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy.
| | - G Francolini
- Radiation Oncology Unit, University of Florence, Florence, Italy
- CyberKnife Center, Istituto Fiorentino di Cura ed Assistenza, Florence, Italy
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - L P Ciccone
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - G Stocchi
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - V Salvestrini
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - M Aquilano
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| | - D Greto
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - P Bonomo
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - I Meattini
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - V Scotti
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - S Scoccianti
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - G Simontacchi
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - L Livi
- Department of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 85, 50134, Florence, Italy
| |
Collapse
|
16
|
Mangoni M, Salvatore G, Greto D, Sottili M, Talamonti C, Lorenzetti V, Aquilano M, Peruzzi A, Salvestrini V, Visani L, Bonomo P, Scorianz M, Muratori F, Scoccianti G, Campanacci D, Livi L. PD-0067: An ex vivo assay to detect radiosensitization by PARP-inhibitors in soft tissue sarcomas. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00093-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Visani L, Saieva C, Desideri I, Scotti V, Dominici L, Scoccimarro E, Aquilano M, Cerbai C, Palmieri V, Maragna V, Becherini C, Bernini M, Sanchez L, Orzalesi L, Nori J, Antonuzzo L, Bianchi S, Meattini I, Livi L. PO-0928: Safety and efficacy of concomitant RT and CDK4/6 inhibitors in metastatic breast cancer patients. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00945-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Francolini G, Garlatti P, Detti B, Bruni A, Mantini G, Pergolizzi S, Borghetti P, D’Angelillo R, Alongi F, Jereczek-Fossa B, Franzese C, Tagliagambe A, Di Cataldo V, Aquilano M, Mariotti M, Salvestrini V, Ciccone L, Stocchi G, Livi L. Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration resistant prostate cancer undergoing I line treatment with abiraterone acetate (ARTO trial-NCT03449719). EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)36207-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
19
|
Francolini G, Salvestrini V, Loi M, Mangoni M, Detti B, Pinzani P, Salvianti F, Desideri I, Aquilano M, Mariotti M, Garlatti P, Stocchi G, Ciccone L, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L. 671P Prospective assessment of AR splice variant and PSMA detection on circulating tumour cells of mCRPC patients: Preliminary results of PRIMERA trial (NCT04188275). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
20
|
Maremmani C, Bongioanni P, Cavallo F, Esposito D, Rovini E, Aquilano M, Carrozza M, Dario P. Preliminary evaluation of Sensorfoot V1 and Senshand V1 in assessing motor skills performance of Parkinson's disease patients. J Neurol Sci 2013. [DOI: 10.1016/j.jns.2013.07.512] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
21
|
|
22
|
Cavallo F, Aquilano M, Bonaccorsi M, Mannari I, Carrozza MC, Dario P. Multidisciplinary approach for developing a new robotic system for domiciliary assistance to elderly people. Annu Int Conf IEEE Eng Med Biol Soc 2011; 2011:5327-5330. [PMID: 22255541 DOI: 10.1109/iembs.2011.6091318] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
This paper aims to show the effectiveness of a (inter / multi)disciplinary team, based on the technology developers, elderly care organizations, and designers, in developing the ASTRO robotic system for domiciliary assistance to elderly people. The main issues presented in this work concern the improvement of robot's behavior by means of a smart sensor network able to share information with the robot for localization and navigation, and the design of the robot's appearance and functionalities by means of a substantial analysis of users' requirements and attitude to robotic technology to improve acceptability and usability.
Collapse
Affiliation(s)
- F Cavallo
- BioRobotics Institute of Scuola Superiore Sant’Anna, Pisa, Italy.
| | | | | | | | | | | |
Collapse
|